Alvotech, Teva Reports FDA Approval For SELARSDI (Ustekinumab-aekn) In New Presentation, 130 Mg/26 Ml (5 Mg/Ml) Solution In Single-dose Vial For Intravenous Infusion
Express News | Teva Pharmaceutical Industries Ltd - Selarsdi U.S. Launch Expected in Q1 2025
Biden, Harris Propose Free OTC Contraception Under ACA
Teva Pharmaceutical Indus Analyst Ratings
J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Hold Rating, Raises Target Price to $18
With 67% Ownership in Teva Pharmaceutical Industries Limited (NYSE:TEVA), Institutional Investors Have a Lot Riding on the Business